PDL BioPharma, Inc. (PDLI) Reaches $3.23 52-Week High; Colg…

PDL BioPharma, Inc. (NASDAQ:PDLI) Logo

The stock of PDL BioPharma, Inc. (NASDAQ:PDLI) hit a new 52-week high and has $3.52 target or 9.00% above today’s $3.23 share price. The 7 months bullish chart indicates low risk for the $470.77 million company. The 1-year high was reported on Feb, 5 by Barchart.com. If the $3.52 price target is reached, the company will be worth $42.37M more. The stock increased 0.47% or $0.015 during the last trading session, reaching $3.225. About 524,053 shares traded. PDL BioPharma, Inc. (NASDAQ:PDLI) has risen 7.89% since February 5, 2018 and is uptrending. It has outperformed by 7.89% the S&P500. Some Historical PDLI News: 09/03/2018 – PDL BioPharma Closes Above 50-Day Moving Average: Technicals; 08/03/2018 – PDL BioPharma 4Q EPS 15c; 08/03/2018 – PDL BioPharma 4Q Rev $68M; 01/05/2018 – HORIZON SAYS TO PRESENT TO PNG MINISER ON PDL 10 STATUS; 01/05/2018 – HORIZON OIL SAYS REPORTS THAT PDL 10 CANCELLED ARE FALSE; 09/04/2018 – PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Deli; 09/04/2018 – SEVENSAOI CAPITAL – SEVENSAOI’S LETTER TO BOARD OF PDL BIOPHARMA DETAILS 3 MAIN AREAS OF CONCERN, LIKE POOR CAPITAL ALLOCATION, ACQUISITION PRACTICES; 07/03/2018 Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharm; 08/03/2018 – PDL BioPharma 4Q Net $22.3M; 09/04/2018 – PDL BIOPHARMA HOLDER SAYS ENCOURAGED BY SHLOMO YANAI NOMINATION

Colgate-palmolive Company (NYSE:CL) had a decrease of 7.36% in short interest. CL’s SI was 10.84M shares in February as released by FINRA. Its down 7.36% from 11.70 million shares previously. With 6.37 million avg volume, 2 days are for Colgate-palmolive Company (NYSE:CL)’s short sellers to cover CL’s short positions. The SI to Colgate-palmolive Company’s float is 1.34%. The stock decreased 0.28% or $0.18 during the last trading session, reaching $65.01. About 1.08 million shares traded. Colgate-Palmolive Company (NYSE:CL) has declined 13.20% since February 5, 2018 and is downtrending. It has underperformed by 13.20% the S&P500. Some Historical CL News: 23/03/2018 – On World Water Day 2018, Colgate Asks People To Turn Off The Faucet While Brushing; 27/04/2018 – COLGATE-PALMOLIVE CO SAYS “UNCERTAINTY IN GLOBAL MARKETS AND CATEGORY GROWTH WORLDWIDE REMAIN CHALLENGING”; 04/05/2018 – COLGATE-PALMOLIVE CO – HICKEY WILL ASSUME ROLE OF VICE CHAIRMAN; 20/04/2018 – DJ Colgate-Palmolive Company, Inst Holders, 1Q 2018 (CL); 29/05/2018 – Colgate-Palmolive Presenting at Deutsche Bank Conference Jun 12; 21/05/2018 – COLGATE INDIA 4Q REV. 10.9B RUPEES; 27/04/2018 – Colgate-Palmolive 1Q Net $634M; 04/05/2018 – Colgate Appoints Henning Jakobsen As Chief Financial Officer And Dennis Hickey As Vice Chairman; 27/04/2018 – Colgate’s sales disappoint on tepid emerging market demand; 21/05/2018 – COLGATE INDIA 4Q TOTAL COSTS 8.25B RUPEES

Analysts await PDL BioPharma, Inc. (NASDAQ:PDLI) to report earnings on March, 14. They expect $0.08 earnings per share, down 52.94% or $0.09 from last year’s $0.17 per share. PDLI’s profit will be $11.68 million for 10.08 P/E if the $0.08 EPS becomes a reality. After $0.07 actual earnings per share reported by PDL BioPharma, Inc. for the previous quarter, Wall Street now forecasts 14.29% EPS growth.

Investors sentiment increased to 0.76 in Q3 2018. Its up 0.13, from 0.63 in 2018Q2. It is positive, as 17 investors sold PDL BioPharma, Inc. shares while 49 reduced holdings. 19 funds opened positions while 31 raised stakes. 123.16 million shares or 0.63% more from 122.39 million shares in 2018Q2 were reported. Wilbanks Smith & Thomas Asset Management Limited Company holds 0% in PDL BioPharma, Inc. (NASDAQ:PDLI) or 1,320 shares. Amalgamated Comml Bank accumulated 19,986 shares. Eqis Management Inc owns 127,504 shares or 0.02% of their US portfolio. Paloma Prtn accumulated 0.01% or 203,900 shares. Wellington Llp has 0% invested in PDL BioPharma, Inc. (NASDAQ:PDLI). Bnp Paribas Arbitrage Sa holds 9,667 shares or 0% of its portfolio. Shell Asset Co owns 146,408 shares. Secor Cap Advsrs L P owns 0.04% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 123,296 shares. Parametric Port Assocs holds 1.20 million shares or 0% of its portfolio. Jane Street Gru Limited Liability Corporation holds 0% of its portfolio in PDL BioPharma, Inc. (NASDAQ:PDLI) for 25,434 shares. Franklin Street Advisors Nc invested in 20,000 shares or 0.01% of the stock. Rbf Cap Ltd Liability Company reported 173,090 shares. Goldman Sachs Group Inc stated it has 168,529 shares. Public Employees Retirement Association Of Colorado holds 0% or 57,000 shares in its portfolio. 15,188 were accumulated by Oppenheimer & Co.

More notable recent PDL BioPharma, Inc. (NASDAQ:PDLI) news were published by: Finance.Yahoo.com which released: “The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study – Yahoo! Finance News” on January 09, 2019, also Nasdaq.com with their article: “Is PDL BioPharma (PDLI) a Great Stock for Value Investors? – Nasdaq” published on September 21, 2018, Nasdaq.com published: “Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report? – Nasdaq” on September 07, 2018. More interesting news about PDL BioPharma, Inc. (NASDAQ:PDLI) were released by: Seekingalpha.com and their article: “Another $145 Million For PDL BioPharma? – Seeking Alpha” published on March 02, 2018 as well as Seekingalpha.com‘s news article titled: “PDL Biopharma: Activist Investor, Enter Stage Right – Seeking Alpha” with publication date: April 27, 2018.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $470.77 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It currently has negative earnings. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

Colgate-Palmolive Company, together with its subsidiaries, makes and sells consumer products worldwide. The company has market cap of $56.38 billion. It operates through two divisions, Oral, Personal and Home Care; and Pet Nutrition. It has a 23.64 P/E ratio. The firm offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other related products.

Among 8 analysts covering Colgate-Palmolive (NYSE:CL), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Colgate-Palmolive had 10 analyst reports since September 18, 2018 according to SRatingsIntel. The firm earned “Market Perform” rating on Wednesday, October 17 by Wells Fargo. The firm has “Buy” rating given on Wednesday, January 9 by Goldman Sachs. The firm has “Hold” rating given on Monday, October 29 by SunTrust. Citigroup maintained the shares of CL in report on Monday, October 29 with “Neutral” rating. Argus Research maintained the stock with “Buy” rating in Tuesday, October 30 report. The firm has “Buy” rating given on Tuesday, September 18 by Argus Research. JP Morgan downgraded the shares of CL in report on Monday, October 29 to “Underweight” rating. Wells Fargo maintained the stock with “Market Perform” rating in Monday, October 29 report.

Since August 13, 2018, it had 0 insider purchases, and 7 sales for $11.19 million activity. $372,590 worth of Colgate-Palmolive Company (NYSE:CL) shares were sold by CAHILL JOHN T. 15,000 shares were sold by MOISON FRANCK J, worth $978,572. On Tuesday, September 11 the insider JAKOBSEN HENNING I sold $68,060. On Monday, August 13 the insider Deoras Mukul sold $737,863. Shotts Philip G. also sold $1.11 million worth of Colgate-Palmolive Company (NYSE:CL) shares. $7.89 million worth of Colgate-Palmolive Company (NYSE:CL) shares were sold by HICKEY DENNIS J.

More notable recent Colgate-Palmolive Company (NYSE:CL) news were published by: 247Wallst.com which released: “Top Trending Google Internet Search Queries Can Be Huge for Stocks – 24/7 Wall St.” on February 05, 2019, also Seekingalpha.com with their article: “Stocks To Watch: Disney, Alphabet And Super Bowl Players – Seeking Alpha” published on February 02, 2019, Seekingalpha.com published: “The 3 Best Dividend Kings For 2019 – Seeking Alpha” on January 09, 2019. More interesting news about Colgate-Palmolive Company (NYSE:CL) were released by: Bizjournals.com and their article: “Atlanta’s Focus Brands adds Coca-Cola exec as part of Jamba Juice leadership restructuring – Atlanta Business Chronicle” published on January 22, 2019 as well as Seekingalpha.com‘s news article titled: “Colgate-Palmolive: Take Profits Now – Seeking Alpha” with publication date: December 10, 2018.

Investors sentiment decreased to 0.8 in 2018 Q3. Its down 0.01, from 0.81 in 2018Q2. It dropped, as 37 investors sold Colgate-Palmolive Company shares while 441 reduced holdings. 90 funds opened positions while 291 raised stakes. 607.72 million shares or 0.75% less from 612.32 million shares in 2018Q2 were reported. Hendley invested in 6,060 shares or 0.2% of the stock. 302 are held by Financial Engines Limited Liability Com. Hartford Fin Mngmt invested 0.11% of its portfolio in Colgate-Palmolive Company (NYSE:CL). 682,671 were reported by Susquehanna Grp Inc Limited Liability Partnership. Plante Moran Advsrs Limited Liability invested in 2,971 shares or 0.06% of the stock. Yacktman Asset Mngmt Lp has 1.25 million shares for 1% of their portfolio. Generation Management Llp accumulated 1.65 million shares. Vigilant Capital Management Ltd Liability Com reported 13,378 shares stake. Sawgrass Asset Lc stated it has 0.04% of its portfolio in Colgate-Palmolive Company (NYSE:CL). Bb&T Securities Limited Liability owns 107,901 shares for 0.07% of their portfolio. 1,625 are held by Howe And Rusling Incorporated. Aviva Public Limited Company holds 424,868 shares. Lombard Odier Asset Mngmt (Europe) Ltd has 21,867 shares. Kentucky Retirement Sys Insurance Fund owns 16,391 shares or 0.24% of their US portfolio. Alphamark Advsr Ltd, Kentucky-based fund reported 1,669 shares.

PDL BioPharma, Inc. (NASDAQ:PDLI) Institutional Positions Chart

Cludo News

Be the first to comment

Leave a Reply

Your email address will not be published.